The Woburn, Mass.-based firm’s product is used during lithotripsy kidney stone treatments that use laser or other energy sources to break up the stones. BackStop uses Pluromed’s Rapid Transition Polymers, which are liquid at low temperatures but gel at 98.6 degrees Fahrenheit. The product won 510(k) approval from the Food & Drug Administration last month.
Pluromed said BackStop is also approved for sale in Europe and Canada. CEO Jean-Marie Vogel said the deal with Boston Scientific allows it to focus on growing its core cardiovascular business.
The two companies will work to integrate the Pluromed product into BSX’s systems ahead of a worldwide product launch.